Table 3 Selected baseline characteristics reported by the included studies
Baseline characteristic | GENEVA | BRAVO | CRUISE | |||
|---|---|---|---|---|---|---|
Sham (n = 426) | Dexamethasone (0.7 mg) (n = 427) | Sham (n = 132) | Ranibizumab (0.5 mg) (n = 131) | Sham (n = 130) | Ranibizumab (0.5 mg) (n = 130) | |
Mean age (range) (yrs) | 63.9 (31–91) | 64.7 (33–90) | 65.2 (26–89) | 67.5 (41–91) | 65.4 (20–91) | 67.6 (40–91) |
Male (%) | 56.3 | 50.8 | 56.1 | 54.2 | 55.4 | 61.5 |
Race Caucasian (%) | 74.6 | 75.2 | 81.8 | 81.7 | 86.9 | 83.1 |
Mean duration macular oedema* (range) | 156.1 (19–374) | 157.6 (19–374) | 114.7 (0–496) | 102.3 (0–403) | 89.9 (0–434)) | 102.3 (0–837) |
Mean baseline visual acuitity BCVA (sd) | 54.8 (9.86) | 54.3 (9.93) | 54.7 (12.2) | 53.0 (12.5) | 49.2 (14.7) | 48.1 (14.6) |
Mean baseline retinal thickness (SD) (µm) | 539 (186) | 562 (188) | NR | NR | NR | NR |
Fellow eye BCVA (ETDRS letters), mean (SD) | NR | NR | 79.8 (17.4) | 81.4 (13.8) | 78.9 (18.6) | 78.8 (17.4) |